ValuEngine downgraded shares of Zafgen, Inc. (NASDAQ:ZFGN) from a sell rating to a strong sell rating in a report issued on Tuesday morning.
Separately, Zacks Investment Research downgraded shares of Zafgen from a buy rating to a hold rating in a report on Saturday, September 9th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and one has assigned a buy rating to the stock. The company has an average rating of Hold and a consensus price target of $6.38.
Shares of Zafgen (NASDAQ ZFGN) opened at 4.03 on Tuesday. The company’s market capitalization is $110.76 million. Zafgen has a one year low of $2.89 and a one year high of $5.46. The firm has a 50-day moving average of $3.48 and a 200-day moving average of $3.87.
Zafgen (NASDAQ:ZFGN) last released its quarterly earnings data on Tuesday, August 8th. The biopharmaceutical company reported ($0.49) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.52) by $0.03. During the same quarter last year, the company earned ($0.55) earnings per share. Equities research analysts expect that Zafgen will post ($2.23) EPS for the current fiscal year.
TRADEMARK VIOLATION WARNING: This report was first reported by Sports Perspectives and is owned by of Sports Perspectives. If you are accessing this report on another domain, it was stolen and reposted in violation of U.S. & international copyright legislation. The legal version of this report can be read at https://sportsperspectives.com/2017/10/13/zafgen-inc-zfgn-cut-to-strong-sell-at-valuengine.html.
Several large investors have recently added to or reduced their stakes in the business. Algert Global LLC acquired a new position in shares of Zafgen in the second quarter valued at about $123,000. Parametric Portfolio Associates LLC grew its stake in shares of Zafgen by 55.8% in the first quarter. Parametric Portfolio Associates LLC now owns 28,832 shares of the biopharmaceutical company’s stock valued at $134,000 after acquiring an additional 10,327 shares in the last quarter. Wells Fargo & Company MN grew its stake in shares of Zafgen by 1,290.3% in the first quarter. Wells Fargo & Company MN now owns 43,531 shares of the biopharmaceutical company’s stock valued at $203,000 after acquiring an additional 40,400 shares in the last quarter. GSA Capital Partners LLP acquired a new position in shares of Zafgen in the second quarter valued at about $259,000. Finally, LMR Partners LLP acquired a new position in shares of Zafgen in the second quarter valued at about $299,000. Hedge funds and other institutional investors own 48.52% of the company’s stock.
Zafgen Company Profile
Zafgen, Inc is a biopharmaceutical company. The Company is focused on improving the health and well-being of patients affected by obesity and complex metabolic disorders. The Company’s lead product candidate, Beloranib, is a twice-weekly subcutaneous injection being developed for the treatment of multiple indications, including severe obesity in rare diseases, such as Prader-Willi syndrome (PWS) and hypothalamic injury-associated obesity (HIAO), including craniopharyngioma-associated obesity.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Zafgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zafgen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.